ReviewBioconjugate chemistry2020
Enhancing Combined Immunotherapy and Radiotherapy through Nanomedicine.
Review in Bioconjugate chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Nanomaterials reshaping cancer radiotherapy: Radiosensitization mechanisms, delivery and theranostic platforms, multimodal synergy, and clinical translation strategies.Materials today. Bio · 2026Review
- Lanthanide Nanotheranostics in Radiotherapy.International journal of molecular sciences · 2025Review
- PRIMERS: Polydopamine Radioimmunotherapy with Image-Guided Monitoring and Enhanced Release System.Pharmaceutics · 2024Article
- Cancer immunotherapy and its facilitation by nanomedicine.Biomarker research · 2024Review
- Current research trends of nanomedicines.Acta pharmaceutica Sinica. B · 2023Review
- Nanoparticles augment the therapeutic window of RT and immunotherapy for treating cancers: pivotal role of autophagy.Theranostics · 2023Review
- Recent Trends and Opportunities for the Targeted Immuno-Nanomaterials for Cancer Theranostics Applications.Micromachines · 2022Review
- 3D printed drug-loaded implantable devices for intraoperative treatment of cancer.Journal of controlled release : official journal of the Controlled Release Society · 2022Article
- Recent advances in nano-drug delivery systems for synergistic antitumor immunotherapy.Frontiers in bioengineering and biotechnology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Radiotherapy and immunotherapy are two key treatments for cancer. There is growing evidence that they are also synergistic, and combination treatments are being studied extensively in the clinical setting. In addition, there is emerging evidence that nanotechnology-enabled therapeutics can potentiate both radiotherapy and immunotherapy, in turn improving both treatments. This is an exciting new area of interdisciplinary science and has significant potential for major clinical impact. Some of the approaches in this area have already reached the clinical stage. In this review, we will discuss recent advances in the interface between radiotherapy, immunotherapy, and nanomedicine. We plan to review the many approaches to combine these three fields for cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.